CME Group
CME
$280.46
+1.79%
CME Group Inc. operates the world's largest derivatives marketplace, providing investors, businesses, and institutions with the ability to trade futures and options across interest rates, equity indexes, foreign currencies, energy, metals, and agricultural commodities, while also generating revenue from market data and clearing services. As the dominant exchange operator in global futures, CME holds a structural near-monopoly in U.S. interest-rate hedging through its exclusive rights to trade and clear S&P futures and its 27% stake in S&P Dow Jones Indexes, giving it a distinct competitive moat built on network effects, liquidity depth, and regulatory entrenchment. The current investor narrative is dominated by the macro rate environment: with Fed Chair Kevin Warsh signaling a hawkish stance and the odds of a September rate hike nearly doubling, volatility expectations are rising, which paradoxically benefits CME's core transaction-fee engine as hedging demand increases. At the same time, the stock has lagged the broader market significantly over the past year, with investors debating whether elevated rate uncertainty is a tailwind for trading volumes or a headwind for the multiple, given the company's premium valuation and near-full dividend payout ratio.…
CME
CME Group
$280.46
Related headlines
Investment Opinion: Should I buy CME Today?
The synthesized recommendation is Hold. CME is a high-quality, wide-moat exchange operator with exceptional profitability and a strong balance sheet, but the current valuation appears full, with the average analyst target of $283.60 implying only 2.9% upside and a consensus rating of 'hold' (mean 2.625). The core thesis is that the stock is fairly valued, offering a 4.00% dividend yield and defensive characteristics, but lacks a near-term catalyst for significant multiple expansion.
Supporting evidence includes: 1) Revenue growth of 14.48% year-over-year in Q1 2026, with net margin expanding to 61.4%; 2) Trailing free cash flow of $4.33 billion, comfortably covering dividends; 3) A low beta of 0.275 and a 4.00% dividend yield, appealing to income and defensive investors; 4) The forward PE of 21.32x is reasonable relative to the company's growth and quality, but the PEG of 1.59 suggests a slight premium. The stock's 6-month relative underperformance of -26.9% versus SPY may present a value opportunity, but the recent 1-month outperformance of +6.16% suggests some recovery is already priced in.
Key risks that could invalidate the Hold rating include: 1) A decline in trading volumes if volatility subsides, which would pressure revenue and earnings; 2) The high payout ratio of 97.2% limiting dividend growth and increasing vulnerability to earnings declines; 3) Valuation compression if interest rates rise further, reducing the attractiveness of dividend stocks. The rating would upgrade to Buy if the stock pulls back to the $230-$240 range (analyst low target) or if trading volumes accelerate sustainably, pushing EPS above $16.50. It would downgrade to Sell if revenue growth decelerates below 10% or if the dividend is cut. Relative to its history and peers, CME appears fairly valued, trading near the midpoint of its recent PE range.
Sign up to view all
CME 12-Month Price Forecast
CME is a high-quality, wide-moat business with strong profitability and a fortress balance sheet, but the stock appears fairly valued with limited near-term upside. The neutral stance reflects a balance between the company's structural strengths and the cyclical risks facing trading volumes. The low beta and attractive dividend yield make it a suitable defensive holding, but the premium valuation and high payout ratio limit upside. I would upgrade to bullish if trading volumes accelerate sustainably, pushing EPS above $16.50, or if the stock pulls back to the $230-$240 range. I would downgrade to bearish if revenue growth decelerates below 10% or if the dividend is cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CME Group's 12-month outlook, with a consensus price target around $283.60 and implied upside of +1.1% versus the current price.
Average Target
$283.60
0 analysts
Implied Upside
+1.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$230 - $330
Analyst target range
CME is covered by 15 analysts, with a consensus recommendation of "hold" and a recommendation mean of 2.625 on a scale where 1 is a strong buy and 5 is a strong sell. The average price target of $283.60 implies approximately +2.9% upside from the current price of $275.54, indicating that the consensus view is that the stock is roughly fairly valued at current levels. The consensus leans neutral-to-slightly-bearish, with the hold rating reflecting a balance between the company's strong fundamentals and the view that much of the positive outlook is already priced in. The estimated EPS average of $16.05 and revenue average of $8.73 billion for the forward period suggest analysts expect continued mid-single-digit to low-double-digit growth.
The target price range spans from a low of $230.00 to a high of $330.00, representing a spread of $100 or approximately 36% of the current price, which signals meaningful uncertainty about the company's trajectory. The high target of $330 implies roughly 19.8% upside and would require either multiple expansion or a significant acceleration in trading volumes, potentially driven by a sustained period of elevated market volatility and Fed policy uncertainty. The low target of $230 implies approximately -16.5% downside and likely prices in a scenario of declining trading volumes, margin compression from competitive pressures, or a broader market correction that reduces hedging activity. Institutional ratings show a predominantly constructive tone, with recent actions including Keefe Bruyette & Woods upgrading to Outperform from Market Perform on June 18, 2026, and Rothschild & Co upgrading to Buy from Neutral on June 11, 2026, while Piper Sandler, Morgan Stanley, and Raymond James have maintained their Overweight/Outperform ratings. The wide target spread, combined with the mix of upgrades and maintained neutral ratings, suggests that while analysts recognize CME's structural strengths, there is genuine debate about whether the current valuation adequately compensates for the cyclical risks facing the exchange business.
Bulls vs Bears: CME Investment Factors
The bull case rests on CME's structural moat, accelerating revenue growth, and the potential for increased hedging activity due to Fed hawkishness. The bear case emphasizes the premium valuation, high payout ratio, and cyclical volume risk. Currently, the bear evidence appears slightly stronger because the stock trades near fair value with limited analyst upside and faces near-term volume uncertainty. The most critical tension is whether elevated rate uncertainty will translate into sustained trading volume growth or merely a temporary spike, which will determine if the premium multiple is justified.
Bullish
- Revenue growth accelerating with operating leverage: Q1 2026 revenue of $1.88 billion grew 14.48% year-over-year, accelerating from prior quarters, while net margin expanded from 58.2% in Q1 2025 to 61.4% in Q1 2026. This demonstrates that incremental trading volume flows through at very high margins, boosting profitability.
- Fortress balance sheet and massive cash generation: Debt-to-equity is only 0.131 and the current ratio is 92.97, reflecting $167.4 billion in cash and investments. Trailing free cash flow of $4.33 billion comfortably covers the $2.70 billion annual dividend, despite a high payout ratio.
- Structural moat and near-monopoly in derivatives: CME holds exclusive rights to trade and clear S&P futures and owns a 27% stake in S&P Dow Jones Indexes, creating a regulatory and network-effect moat. This dominance in U.S. interest-rate hedging is difficult to replicate.
- Hawkish Fed and rate uncertainty drive hedging demand: Fed Chair Warsh's hawkish stance and rising odds of a September rate hike increase volatility expectations, which historically boosts CME's transaction-fee revenue as clients hedge interest-rate risk. Recent news highlights the doubling of rate-hike odds, a potential volume catalyst.
Bearish
- Premium valuation with limited upside to targets: The trailing PE of 24.43x and forward PE of 21.32x are premium multiples, and the average analyst target of $283.60 implies only 2.9% upside. The PEG ratio of 1.59 suggests the stock is fully valued relative to its growth rate.
- Unsustainable dividend payout ratio: The payout ratio of 97.2% leaves almost no room for error; any earnings decline could force a dividend cut or halt increases. This is a significant risk for income investors relying on the 4.00% yield.
- Cyclical exposure to trading volumes: With 82% of revenue from clearing and transaction fees, CME is highly sensitive to market volatility. A normalization in volatility or a decline in trading activity could pressure revenue and earnings.
- Recent underperformance and technical weakness: The stock has lagged the S&P 500 by 11.2% over the past year and 26.9% over six months, with a max drawdown of -33.05%. The 6-month change of -11.52% indicates persistent selling pressure despite a recent bounce.
CME Technical Analysis
CME is in a recovery phase within a broader range-bound consolidation, with the current price of $275.54 sitting at approximately 51.7% of its 52-week range (low of $218.31, high of $329.16). The 1-year price change of +5.02% masks significant intra-year volatility, including a max drawdown of -33.05% that saw the stock plunge from its highs near $329 to a trough around $218 in late June 2026. This mid-range positioning suggests the stock is neither overextended nor deeply discounted, but the recovery from the June lows has been steady, implying that buyers have regained control without triggering overbought conditions. The 6-month change of -11.52% underscores that the stock is still repairing damage from the first-half selloff, while the YTD gain of +2.17% indicates a modest but positive annual performance.
Recent momentum is clearly positive and accelerating on a short-term basis, with a 1-month gain of +5.10% and a 3-month gain of +2.23%, both representing a sharp reversal from the 6-month decline of -11.52%. The relative strength versus SPY over the past month is +6.16 percentage points, meaning CME has significantly outperformed the broader market during this recovery window, even as SPY declined -1.06% over the same period. However, the 1-year relative strength of -11.20% and 6-month relative strength of -26.92% reveal that this recent outperformance is a rebound within a longer-term period of underperformance. The divergence between the strong 1-month momentum and the weak 6-month trend signals a potential trend reversal in progress, though the stock has pulled back modestly from its late-August peak of $286.45 to the current $275.54, suggesting some near-term consolidation after the sharp rally.
Key technical resistance sits at the 52-week high of $329.16, which represents roughly 19.5% upside from the current price, while immediate support is anchored near the 52-week low of $218.31, approximately 20.8% below current levels. A breakout above the $286-$290 area (the recent August highs) would confirm the recovery trend and open a path toward the $300+ zone, while a breakdown below the $260 support level would signal a retest of the June lows. The beta of 0.275 is remarkably low, indicating that CME is roughly 72.5% less volatile than the broader market, which makes it an attractive defensive holding but also means it will likely lag in strong risk-on rallies. This low beta, combined with a short ratio of 2.9 days, suggests limited speculative pressure and a shareholder base skewed toward long-term institutional holders, which supports price stability but may cap explosive upside moves.
Beta
0.28
0.28x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$218-$329
Price range past year
Annual Return
+6.9%
Cumulative gain past year
| Period | CME Return | S&P 500 |
|---|---|---|
| 1m | +4.0% | -2.0% |
| 3m | +7.2% | +1.4% |
| 6m | -9.2% | +15.0% |
| 1y | +6.9% | +15.7% |
| ytd | +4.0% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CME Fundamental Analysis
CME's revenue trajectory remains solidly growth-oriented, with Q1 2026 revenue of $1.88 billion representing a 14.48% year-over-year increase from Q1 2025's $1.64 billion, marking an acceleration from the prior quarters. The sequential trend shows Q1 2026 revenue of $1.88 billion surpassing Q4 2025's $1.65 billion and Q3 2025's $1.54 billion, confirming that growth is not only sustained but accelerating. The revenue mix is heavily weighted toward clearing and transaction fees at $1.54 billion, with market data contributing $224.1 million and other revenue at $113.4 million, meaning the company's fortunes are tightly linked to trading volumes and market volatility. This concentration in transaction fees is a double-edged sword: it provides high operating leverage during volatile periods but exposes the company to volume cyclicality if market activity normalizes.
Profitability is exceptional, with Q1 2026 net income of $1.15 billion on $1.88 billion in revenue, yielding a net margin of 61.4% and a gross margin of 88.1%. The operating margin of 69.7% in Q1 2026 reflects the inherent scalability of the exchange model, where incremental volume generates disproportionately high margins. Comparing across recent quarters, net income has been remarkably stable: $1.15 billion in Q1 2026, $1.17 billion in Q4 2025, $908 million in Q3 2025, and $1.01 billion in Q2 2025, with the Q3 2025 dip likely reflecting seasonal volume patterns. The net margin has expanded from 58.2% in Q1 2025 to 61.4% in Q1 2026, demonstrating positive operating leverage as revenue growth outpaces cost growth.
The balance sheet is fortress-like, with a debt-to-equity ratio of just 0.131 and a current ratio of 92.97, reflecting the company's massive cash and investment holdings of $167.4 billion as of Q1 2026. Free cash flow on a trailing twelve-month basis is $4.33 billion, comfortably covering the $2.70 billion in dividends paid during Q1 2026, though the payout ratio of 97.2% leaves little room for error if earnings decline. Return on equity stands at 14.08%, which is healthy for a capital-light exchange business, while the ROA of 1.48% appears low only because of the enormous balance sheet assets related to clearing operations. The company generates more than enough cash internally to fund operations and capital expenditures of just $21.8 million in Q1 2026, with the primary use of cash being shareholder returns through dividends and modest buybacks of $538.7 million.
Quarterly Revenue
$1.9B
2026-03
Revenue YoY Growth
+14.5%
YoY Comparison
Gross Margin
88.1%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CME Overvalued?
Because CME is solidly profitable with trailing net income of $1.15 billion in the most recent quarter, the PE ratio is the appropriate primary valuation metric. The trailing PE of 24.43x compares to a forward PE of 21.32x, implying that the market expects earnings growth of approximately 14.6% over the next twelve months, which is consistent with the analyst consensus EPS estimate of $16.05 versus the trailing EPS of $0.041 (which appears distorted by data anomalies). The gap between trailing and forward PE suggests the market is pricing in moderate earnings expansion, likely driven by continued volume growth and operating leverage.
Relative to the broader financial services and exchange sector, CME's valuation presents a mixed picture. The price-to-sales ratio of 15.06x and EV/EBITDA of 17.05x are premium multiples that reflect the company's exceptional 62.0% net margin and 86.1% gross margin, which are among the highest in the financial sector. The price-to-book ratio of 3.42x is elevated relative to traditional financial institutions but justified by the company's asset-light, high-return business model. The PEG ratio of 1.59 suggests the stock is trading at a modest premium to its growth rate, which is reasonable for a company with CME's competitive moat and consistent cash generation. The dividend yield of 4.00% is attractive for income-oriented investors, though the 97.2% payout ratio raises questions about the sustainability of future dividend increases without corresponding earnings growth.
Historically, CME's valuation has oscillated within a relatively defined band, with the PE ratio ranging from a low of approximately 18.7x in Q3 2021 to a high of 37.4x in Q2 2021, and more recently settling in the 21x-27x range over the past eight quarters. The current trailing PE of 24.43x sits near the midpoint of this recent range, suggesting the stock is neither cheap nor expensive relative to its own history. The PS ratio of 15.06x is notably below the historical levels of 45x-63x seen in prior periods, though this discrepancy likely reflects changes in the data calculation methodology rather than a fundamental shift in valuation. The PB ratio of 3.42x is above the 2.2x-2.8x range seen in 2022-2023 but below the 3.99x peak in Q1 2026, indicating that the market has moderated its premium valuation for the stock after the mid-year selloff.
PE
24.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but notable. The 97.2% dividend payout ratio leaves little cushion; a 10% decline in net income could jeopardize the dividend. Revenue concentration in transaction fees (82% of total) ties performance to market volatility, and the current ratio of 92.97, while high, reflects clearinghouse assets that are not freely available. Debt-to-equity of 0.131 is low, but interest expense of $43.6 million in Q1 2026 is a fixed cost. Overall, the balance sheet is strong, but the high payout ratio and revenue cyclicality are key vulnerabilities.
Market and competitive risks include valuation compression if growth slows. The trailing PE of 24.43x is above the historical midpoint of 21x-27x, and the PEG of 1.59 suggests a premium to growth. Competition from other exchanges (e.g., ICE, Cboe) and potential regulatory changes could erode CME's moat. The low beta of 0.275 reduces market correlation but also means the stock may lag in strong bull markets. Recent news of a hawkish Fed could increase volatility, which benefits volumes but may also lead to a market correction that reduces overall trading activity.
The worst-case scenario involves a sharp decline in trading volumes due to a sudden return of low volatility, combined with a dividend cut if earnings fall. This could drive the stock to its 52-week low of $218.31, representing a 20.8% decline from the current price of $275.54. The analyst low target of $230 implies a 16.5% downside. In a severe recession, trading volumes might drop 20-30%, causing earnings to fall and the multiple to compress to the low end of its historical range (18.7x), potentially pushing the stock below $200. Investors could lose 20-30% from current levels in such an adverse scenario.
FAQ
The most severe risk is the high dividend payout ratio of 97.2%, which leaves little room for error if earnings decline. Second, revenue is highly cyclical, with 82% from transaction fees, so a drop in market volatility could significantly reduce trading volumes and revenue. Third, the stock faces valuation compression risk if interest rates rise further, making its 4.00% yield less attractive. Fourth, competitive pressures from other exchanges or regulatory changes could erode its moat. These risks are ranked from most to least immediate, with the payout ratio being the most pressing.
Our 12-month forecast has a base case (55% probability) with a target range of $270-$290, assuming moderate volume growth and stable margins. The bull case (25% probability) targets $310-$330 if volatility spikes and volumes accelerate. The bear case (20% probability) targets $218-$240 if trading volumes decline sharply. The most likely scenario is the base case, hinging on steady interest-rate uncertainty that supports hedging demand without causing a market crash. The average analyst target of $283.60 aligns with our base case.
CME appears fairly valued. The trailing PE of 24.43x and forward PE of 21.32x are in line with its recent historical range of 21x-27x, and the PEG ratio of 1.59 suggests a slight premium to its growth rate. The price-to-sales ratio of 15.06x is high but justified by a 62.0% net margin. Compared to peers like ICE and Cboe, CME often trades at a premium due to its dominant market position. The market is pricing in moderate earnings growth of about 14.6% over the next year, which seems achievable given the current volume trends.
CME is a good buy for income-oriented, risk-averse investors seeking a 4.00% dividend yield and low volatility (beta 0.275). The stock trades at a trailing PE of 24.43x, near its historical average, and the average analyst target of $283.60 implies only 2.9% upside, suggesting limited near-term capital appreciation. The biggest downside risk is a decline in trading volumes if volatility subsides, which could pressure revenue and the dividend (payout ratio 97.2%). For those comfortable with modest growth and a defensive profile, CME is a solid long-term holding, but it may not appeal to investors seeking high growth.
CME is best suited for long-term investment, given its low beta (0.275), stable dividend (4.00% yield), and wide economic moat. Short-term trading is less attractive due to low volatility and limited analyst upside (2.9%). The stock's 6-month relative underperformance (-26.9% vs. SPY) may present a value opportunity for patient investors, but near-term catalysts are lacking. A minimum holding period of 2-3 years is recommended to capture dividend growth and potential multiple expansion. The company's consistent cash flow and dominant market position make it a core holding for income portfolios.